"The Global Hereditary Angioedema Therapeutics Market was valued at USD 9.45 billion in 2025 and is projected to reach USD 36.96 billion by 2034, growing at a CAGR of 16.37%."
The Hereditary Angioedema (HAE) Therapeutics market is a critical segment within the rare disease treatment landscape, focused on managing a genetic disorder characterized by recurrent episodes of severe swelling in various body parts. Caused by C1 inhibitor deficiency or dysfunction, HAE requires targeted therapies to prevent or control acute attacks and reduce the disease burden. The market encompasses a range of treatment modalities including C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and gene therapies. Increased disease awareness, earlier diagnosis, and expanded patient access to novel therapies are accelerating the demand for effective prophylactic and on-demand treatments. Pharmaceutical companies are investing significantly in clinical trials, biologics innovation, and next-generation delivery systems, making this market highly dynamic and innovation-driven.
Ongoing advancements in biotechnology are reshaping the competitive landscape, with subcutaneous and oral therapies gaining traction for their convenience and improved patient adherence. Strategic collaborations between biotech firms and research institutions are expediting the development of new drug candidates, while regulatory bodies continue to support rare disease treatment approvals through accelerated pathways. The market is witnessing robust pipeline activity, especially in long-acting therapies and potential curative approaches through gene editing technologies. With rising emphasis on patient-centric care, digital monitoring tools, and specialty pharmacy integration, the Hereditary Angioedema Therapeutics market is positioned for sustained growth across both developed and emerging healthcare systems.
North America Hereditary Angioedema Therapeutics MarketThe North American Hereditary Angioedema (HAE) therapeutics market is highly advanced, benefiting from strong diagnostics capability, well-established specialty care networks, and broad access to innovative biologic and small-molecule therapies. The region is seeing a marked shift towards personalized prophylactic and on-demand treatment options, including injectable monoclonal antibodies and, most recently, the first oral on-demand therapy. With cutting-edge regulatory support—including orphan drug designations and expedited review pathways—the market is characterized by rapid adoption of novel therapeutics by academic centers, specialty pharmacies, and patient-centric care programs. North America remains the dominant consumer region, with healthcare systems and payers increasingly embracing outcome-driven reimbursement models that support long-acting prophylactics and agent innovations tailored to minimize attack frequency and healthcare burden.
Pipeline activity in North America is robust, with numerous cutting-edge therapies under development—ranging from gene-editing candidates to novel biologics targeting the kallikrein-kinin cascade. Therapeutic convenience, reduced infusion burden, and enhanced patient adherence are key drivers for growth, as both patients and providers favor subcutaneous, oral, and long-acting options. Companies offering integrated care pathways—such as digital monitoring platforms and specialty pharmacy services—are gaining competitive advantage. Market opportunities exist in expanding treatment access via telemedicine, descretized delivery models, and value-based contracting tied to real-world efficacy and quality-of-life outcomes.
Asia Pacific Hereditary Angioedema Therapeutics MarketThe Asia Pacific HAE therapeutics market is the fastest expanding globally, driven by rising awareness, enhanced genetic and diagnostic testing infrastructure, and increased healthcare spending. While the region is still scaling access to advanced HAE therapies, multinational pharmaceutical manufacturers are collaborating with regional institutions to introduce novel treatments. Demand is growing for more convenient oral and injectable options adapted to local healthcare delivery contexts. Multilingual patient education, emerging specialty care networks, and telereach initiatives are enhancing uptake. Companies that customize dosing, delivery, and service models to regional economics and healthcare dynamics are gaining early traction.
Several key pipeline candidates and collaborative research programs are underway in Asia Pacific, focusing on long-acting prosthetic biologics and oral kallikrein inhibitors. Importantly, the introduction of oral on-demand therapy offers a transformational entry point in markets with logistical or cold-chain challenges. Additional opportunities lie in partnering with regional payers to integrate HAE care into rare disease reimbursement schemes and specialty pharmacy distribution. With increasing prevalence of diagnosed HAE and improving payer readiness, Asia Pacific presents a high-growth opportunity for therapies that combine efficacy, convenience, and regional service support.
Europe Hereditary Angioedema Therapeutics MarketThe European HAE therapeutics market is mature in Western Europe and rapidly evolving across Eastern Europe. Regulatory endorsement of novel molecules—including the introduction of a first-in-class monoclonal antibody targeting coagulation factor XIIa and the first oral on-demand therapy—has accelerated market momentum. European healthcare systems emphasize cost-effectiveness, safety compliance, and long-term efficacy, encouraging clinicians to adopt treatments with demonstrated reductions in attack frequency and healthcare utilization. Suppliers offering CE‑certified formulations, patient support programs, and robust post-market data reporting are best positioned for success.
Key growth drivers in Europe include robust investment in specialized care centers, increasing use of genetics-based diagnosis, and integration of HAE treatment into public health remuneration frameworks. Innovative treatments now offer once-monthly subcutaneous prophylaxis and oral acute attack options that enhance patient autonomy and reduce infusion burden. Strategic partnerships between biopharma firms and national health systems—combined with specialty pharmacy distribution and digital adherence tools—are unlocking broader access. Eastern European markets represent untapped potential as infrastructure evolves to align with Western European standards.
Key Insights
The Hereditary Angioedema therapeutics market is witnessing strong growth due to increasing awareness, earlier diagnosis, and the availability of targeted treatments that improve quality of life and reduce hospitalization rates for patients experiencing acute attacks.
Current treatment options include C1 esterase inhibitors, kallikrein inhibitors, and bradykinin receptor antagonists, administered via intravenous, subcutaneous, and oral routes. These therapies are designed for both prophylaxis and acute management, offering flexibility based on disease severity and frequency.
The shift toward subcutaneous and oral therapies is significantly enhancing patient convenience and adherence. These administration routes reduce the burden of frequent hospital visits and enable patients to manage the condition more independently, particularly in homecare settings.
Biopharmaceutical companies are heavily investing in research focused on long-acting treatments and gene therapy-based approaches. These innovations aim to minimize treatment frequency and potentially offer curative solutions for hereditary angioedema in the future.
The regulatory environment is favorable for rare disease therapeutics, with multiple fast-track designations and orphan drug approvals facilitating quicker market access. This trend encourages innovation and accelerates the commercial availability of novel therapies.
North America dominates the market due to robust healthcare infrastructure, high per capita spending, and early adoption of biologics. However, emerging markets in Asia Pacific and Latin America are gaining traction as awareness and healthcare access improve.
Digital health integration is playing a growing role in HAE management, with telemedicine platforms, electronic patient diaries, and remote monitoring tools helping patients and providers track attacks, medication use, and treatment efficacy in real time.
Collaborations between academic research institutions and pharmaceutical companies are driving innovation, particularly in understanding disease mechanisms, developing biomarkers, and designing personalized treatment approaches tailored to genetic profiles.
Specialty pharmacies are becoming integral to therapy distribution, providing cold-chain logistics, adherence programs, and patient education to ensure proper use and reduce discontinuation of therapy in chronic HAE management.
Market competition is intensifying as biosimilars and next-generation molecules enter clinical trials, pressuring established brands to innovate and differentiate through delivery improvements, patient-centric services, and long-term outcome data.
Market Scope
| Parameter | Detail |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2026-2034 |
| Market Size-Units | USD billion |
| Market Splits Covered | By Drug Class , By Route of Administration , By Distribution Channel , By Application |
| Countries Covered | North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) |
| Analysis Covered | Latest Trends, Driving Factors, Challenges, Supply-Chain Analysis, Competitive Landscape, Company Strategies |
| Customization | 10 % free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed |
| Post-Sale Support | 4 analyst hours, available up to 4 weeks |
| Delivery Format | The Latest Updated PDF and Excel Datafile |
Hereditary Angioedema Therapeutics Market Segmentation
By Drug Class
- C1 Esterase Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Other Drug Classes
By Route of Administration
- Intravenous
- Subcutaneous
- Oral
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Other Distribution Channels
By Application
- Prophylaxis
- On-demand
By Geography
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Key Companies Covered
CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., Astria Therapeutics, Inc., Grifols, Swedish Orphan Biovitrum (Sobi), Pfizer Inc., Sanofi, Novartis AG, GSK plc, Amgen Inc., Johnson & Johnson Services, Inc., Bayer AG, Roche.Recent Developments
July 2025: KalVista Pharmaceuticals received FDA approval for Ekterly (sebetralstat), the first and only oral on-demand therapy for acute HAE attacks, offering a non-injectable alternative to existing treatments.
June 2025: CSL gained FDA approval for garadacimab, a first-in-class factor XIIa inhibitor designed for once-monthly subcutaneous prophylactic treatment in hereditary angioedema patients.
June 2025: Intellia Therapeutics released three-year follow-up data for its in-vivo CRISPR therapy lonvo-z, showing sustained elimination of severe HAE attacks from a single gene-editing treatment.
June 2025: Pharvaris shared positive trial results for deucrictibant, its oral B2 receptor antagonist, indicating dual use potential for both prophylactic and on-demand HAE treatment approaches.
May 2025: Ionis Pharmaceuticals announced new Phase 3 findings from the OASIS-plus study for donidalorsen, demonstrating enhanced efficacy and safety for patients transitioning from other HAE prophylactic therapies.
July 2025: KalVista Pharmaceuticals received a positive opinion from the European Medicines Agency's CHMP for Ekterly, supporting upcoming EU approval for the first oral on-demand HAE treatment.
What You Receive
• Global Hereditary Angioedema Therapeutics market size and growth projections (CAGR), 2024- 2034• Impact of recent changes in geopolitical, economic, and trade policies on the demand and supply chain of Hereditary Angioedema Therapeutics.
• Hereditary Angioedema Therapeutics market size, share, and outlook across 5 regions and 27 countries, 2025- 2034.
• Hereditary Angioedema Therapeutics market size, CAGR, and Market Share of key products, applications, and end-user verticals, 2025- 2034.
• Short and long-term Hereditary Angioedema Therapeutics market trends, drivers, restraints, and opportunities.
• Porter’s Five Forces analysis, Technological developments in the Hereditary Angioedema Therapeutics market, Hereditary Angioedema Therapeutics supply chain analysis.
• Hereditary Angioedema Therapeutics trade analysis, Hereditary Angioedema Therapeutics market price analysis, Hereditary Angioedema Therapeutics Value Chain Analysis.
• Profiles of 5 leading companies in the industry- overview, key strategies, financials, and products.
• Latest Hereditary Angioedema Therapeutics market news and developments.
The Hereditary Angioedema Therapeutics Market international scenario is well established in the report with separate chapters on North America Hereditary Angioedema Therapeutics Market, Europe Hereditary Angioedema Therapeutics Market, Asia-Pacific Hereditary Angioedema Therapeutics Market, Middle East and Africa Hereditary Angioedema Therapeutics Market, and South and Central America Hereditary Angioedema Therapeutics Markets. These sections further fragment the regional Hereditary Angioedema Therapeutics market by type, application, end-user, and country.
1.1 List of Tables
1.2 List of Figures
2. Hereditary Angioedema Therapeutics Market Latest Trends, Drivers and Challenges, 2024- 2034
2.1 Hereditary Angioedema Therapeutics Market Overview
2.2 Market Strategies of Leading Hereditary Angioedema Therapeutics Companies
2.3 Hereditary Angioedema Therapeutics Market Insights, 2024- 2034
2.3.1 Leading Hereditary Angioedema Therapeutics Types, 2024- 2034
2.3.2 Leading Hereditary Angioedema Therapeutics End-User industries, 2024- 2034
2.3.3 Fast-Growing countries for Hereditary Angioedema Therapeutics sales, 2024- 2034
2.4 Hereditary Angioedema Therapeutics Market Drivers and Restraints
2.4.1 Hereditary Angioedema Therapeutics Demand Drivers to 2034
2.4.2 Hereditary Angioedema Therapeutics Challenges to 2034
2.5 Hereditary Angioedema Therapeutics Market- Five Forces Analysis
2.5.1 Hereditary Angioedema Therapeutics Industry Attractiveness Index, 2024
2.5.2 Threat of New Entrants
2.5.3 Bargaining Power of Suppliers
2.5.4 Bargaining Power of Buyers
2.5.5 Intensity of Competitive Rivalry
2.5.6 Threat of Substitutes
3. Global Hereditary Angioedema Therapeutics Market Value, Market Share, and Forecast to 2034
3.1 Global Hereditary Angioedema Therapeutics Market Overview, 2024
3.2 Global Hereditary Angioedema Therapeutics Market Revenue and Forecast, 2024- 2034 (US$ billion)
3.3 Global Hereditary Angioedema Therapeutics Market Size and Share Outlook By Product, 2024- 2034
3.4 Global Hereditary Angioedema Therapeutics Market Size and Share Outlook By Application, 2024- 2034
3.5 Global Hereditary Angioedema Therapeutics Market Size and Share Outlook By End User, 2024- 2034
3.6 Global Hereditary Angioedema Therapeutics Market Size and Share Outlook By Technology, 2024- 2034
3.7 Global Hereditary Angioedema Therapeutics Market Size and Share Outlook by Region, 2024- 2034
4. Asia Pacific Hereditary Angioedema Therapeutics Market Value, Market Share and Forecast to 2034
4.1 Asia Pacific Hereditary Angioedema Therapeutics Market Overview, 2024
4.2 Asia Pacific Hereditary Angioedema Therapeutics Market Revenue and Forecast, 2024- 2034 (US$ billion)
4.3 Asia Pacific Hereditary Angioedema Therapeutics Market Size and Share Outlook By Product, 2024- 2034
4.4 Asia Pacific Hereditary Angioedema Therapeutics Market Size and Share Outlook By Application, 2024- 2034
4.5 Asia Pacific Hereditary Angioedema Therapeutics Market Size and Share Outlook By End User, 2024- 2034
4.6 Asia Pacific Hereditary Angioedema Therapeutics Market Size and Share Outlook By Technology, 2024- 2034
4.7 Asia Pacific Hereditary Angioedema Therapeutics Market Size and Share Outlook by Country, 2024- 2034
5. Europe Hereditary Angioedema Therapeutics Market Value, Market Share, and Forecast to 2034
5.1 Europe Hereditary Angioedema Therapeutics Market Overview, 2024
5.2 Europe Hereditary Angioedema Therapeutics Market Revenue and Forecast, 2024- 2034 (US$ billion)
5.3 Europe Hereditary Angioedema Therapeutics Market Size and Share Outlook By Product, 2024- 2034
5.4 Europe Hereditary Angioedema Therapeutics Market Size and Share Outlook By Application, 2024- 2034
5.5 Europe Hereditary Angioedema Therapeutics Market Size and Share Outlook By End User, 2024- 2034
5.6 Europe Hereditary Angioedema Therapeutics Market Size and Share Outlook By Technology, 2024- 2034
5.7 Europe Hereditary Angioedema Therapeutics Market Size and Share Outlook by Country, 2024- 2034
6. North America Hereditary Angioedema Therapeutics Market Value, Market Share and Forecast to 2034
6.1 North America Hereditary Angioedema Therapeutics Market Overview, 2024
6.2 North America Hereditary Angioedema Therapeutics Market Revenue and Forecast, 2024- 2034 (US$ billion)
6.3 North America Hereditary Angioedema Therapeutics Market Size and Share Outlook By Product, 2024- 2034
6.4 North America Hereditary Angioedema Therapeutics Market Size and Share Outlook By Application, 2024- 2034
6.5 North America Hereditary Angioedema Therapeutics Market Size and Share Outlook By End User, 2024- 2034
6.6 North America Hereditary Angioedema Therapeutics Market Size and Share Outlook By Technology, 2024- 2034
6.7 North America Hereditary Angioedema Therapeutics Market Size and Share Outlook by Country, 2024- 2034
7. South and Central America Hereditary Angioedema Therapeutics Market Value, Market Share and Forecast to 2034
7.1 South and Central America Hereditary Angioedema Therapeutics Market Overview, 2024
7.2 South and Central America Hereditary Angioedema Therapeutics Market Revenue and Forecast, 2024- 2034 (US$ billion)
7.3 South and Central America Hereditary Angioedema Therapeutics Market Size and Share Outlook By Product, 2024- 2034
7.4 South and Central America Hereditary Angioedema Therapeutics Market Size and Share Outlook By Application, 2024- 2034
7.5 South and Central America Hereditary Angioedema Therapeutics Market Size and Share Outlook By End User, 2024- 2034
7.6 South and Central America Hereditary Angioedema Therapeutics Market Size and Share Outlook By Technology, 2024- 2034
7.7 South and Central America Hereditary Angioedema Therapeutics Market Size and Share Outlook by Country, 2024- 2034
8. Middle East Africa Hereditary Angioedema Therapeutics Market Value, Market Share and Forecast to 2034
8.1 Middle East Africa Hereditary Angioedema Therapeutics Market Overview, 2024
8.2 Middle East and Africa Hereditary Angioedema Therapeutics Market Revenue and Forecast, 2024- 2034 (US$ billion)
8.3 Middle East Africa Hereditary Angioedema Therapeutics Market Size and Share Outlook By Product, 2024- 2034
8.4 Middle East Africa Hereditary Angioedema Therapeutics Market Size and Share Outlook By Application, 2024- 2034
8.5 Middle East Africa Hereditary Angioedema Therapeutics Market Size and Share Outlook By End User, 2024- 2034
8.6 Middle East Africa Hereditary Angioedema Therapeutics Market Size and Share Outlook By Technology, 2024- 2034
8.7 Middle East Africa Hereditary Angioedema Therapeutics Market Size and Share Outlook by Country, 2024- 2034
9. Hereditary Angioedema Therapeutics Market Structure
9.1 Key Players
9.2 Hereditary Angioedema Therapeutics Companies - Key Strategies and Financial Analysis
9.2.1 Snapshot
9.2.3 Business Description
9.2.4 Products and Services
9.2.5 Financial Analysis
10. Hereditary Angioedema Therapeutics Industry Recent Developments
11 Appendix
11.1 Publisher Expertise
11.2 Research Methodology
11.3 Annual Subscription Plans
11.4 Contact Information
Get Free Sample
At OG Analysis, we understand the importance of informed decision-making in today's dynamic business landscape. To help you experience the depth and quality of our market research reports, we offer complimentary samples tailored to your specific needs.
Start Now! Please fill the form below for your free sample.
Why Request a Free Sample?
Evaluate Our Expertise: Our reports are crafted by industry experts and seasoned analysts. Requesting a sample allows you to assess the depth of research and the caliber of insights we provide.
Tailored to Your Needs: Let us know your industry, market segment, or specific topic of interest. Our free samples are customized to ensure relevance to your business objectives.
Witness Actionable Insights: See firsthand how our reports go beyond data, offering actionable insights and strategic recommendations that can drive your business forward.
Embark on your journey towards strategic decision-making by requesting a free sample from OG Analysis. Experience the caliber of insights that can transform the way you approach your business challenges.
FAQ's
The Global Hereditary Angioedema Therapeutics Market is estimated to generate USD 9.45 billion in revenue in 2025.
The Global Hereditary Angioedema Therapeutics Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 16.37% during the forecast period from 2025 to 2034.
The Hereditary Angioedema Therapeutics Market is estimated to reach USD 36.96 billion by 2034.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!
